CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

Phase 1/2 Unknown 10 enrolled PersonGen BioTherapeutics (Suzhou) Co., Ltd. Hefei Binhu Hospital · collab The First People's Hospital of Hefei · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with CD7 positive relapsed or refractory Leukemia and Lymphoma.

Timeline

Start: 2016-03
Primary completion: 2017-03
Completion: 2018-03

Publications

Del Zotto G, Marcenaro E, Vacca P, Sivori S, Pende D, Della Chiesa M, Moretta F, Ingegnere T, Mingari MC, Moretta A, Moretta L. Markers and function of human NK cells in normal and pathological conditions. Cytometry B Clin Cytom. 2017 Mar;92(2):100-114. doi: 10.1002/cyto.b.21508. Epub 2017 Feb 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	anti-CD7 CAR-pNK cells	Cell therapy	—	Other

CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

Summary

Timeline

Publications

Drugs

Indications